sofosbuvir

sofosbuvir is a direct-acting antiviral medication used as part of combination therapy to treat chronic hepatitis C, an infection caused by the hepatitis C virus. It is a nucleotide analog inhibitor that targets the NS5B RNA-dependent RNA polymerase, a key enzyme in the viral replication process. Developed by Pharmasset and later acquired by Gilead Sciences, it is marketed under the brand name Sovaldi and is a cornerstone of modern, interferon-free treatment regimens.

Medical uses

Sofosbuvir is indicated for the treatment of chronic hepatitis C in adults, in combination with other antiviral agents such as ledipasvir, velpatasvir, or voxilaprevir. Its use is guided by the specific genotype of the hepatitis C virus, with high efficacy rates across genotypes 1 through 6. The American Association for the Study of Liver Diseases and the Infectious Diseases Society of America recommend sofosbuvir-based regimens in their joint guidelines. It is also a critical component in treating patients with complications like hepatocellular carcinoma or those who have undergone a liver transplant.

Adverse effects

Common adverse effects associated with sofosbuvir, particularly when used in combination therapies, include fatigue, headache, and nausea. More serious potential effects can involve symptomatic bradycardia when co-administered with amiodarone, a warning highlighted by the U.S. Food and Drug Administration. As with many antiviral drugs, there is a risk of hepatitis B virus reactivation, necessitating screening prior to initiation. The European Medicines Agency also monitors post-marketing safety data for any rare adverse events.

Pharmacology

Sofosbuvir is a prodrug that is metabolized in the liver to its active form, GS-461203, which mimics the natural substrates of the viral NS5B polymerase. This nucleotide analog inhibits the RNA-dependent RNA polymerase of the hepatitis C virus, causing chain termination during viral RNA replication. Pharmacokinetic studies show it has high oral bioavailability and is primarily excreted renally. Its mechanism allows it to be effective against viruses that have developed resistance to other classes of drugs, such as protease inhibitors.

History and society

The compound was discovered by researchers at Pharmasset, a company founded by Raymond Schinazi. Gilead Sciences acquired Pharmasset in 2011 for approximately $11 billion, one of the largest acquisitions in biotechnology history at the time. Following expedited review, the U.S. Food and Drug Administration approved Sovaldi in December 2013. Its high initial list price sparked significant debate about drug pricing, leading to congressional hearings and investigations by committees like the United States Senate Committee on Finance. The drug's introduction marked a paradigm shift in treating hepatitis C, moving away from regimens based on interferon and ribavirin.

Research

Ongoing research explores the use of sofosbuvir in special populations, including pediatric patients and those with severe renal impairment. Studies are also investigating its potential efficacy against other viruses within the Flaviviridae family, such as dengue virus and Zika virus. Clinical trials continue to evaluate next-generation combinations, like sofosbuvir/velpatasvir/voxilaprevir, for patients who have failed prior therapies. Research presented at conferences like the International Liver Congress and published in journals such as the New England Journal of Medicine continues to refine its role in global elimination efforts for hepatitis C.

Category:Antiviral drugs Category:Hepatitis C Category:Gilead Sciences